Findings

What do systematic reviews say?

25 questions · 25 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 12%GRADE not reported 0 · 0%Very low 6 · 24%Low 10 · 40%Moderate 2 · 8%High 4 · 16%

GLP‐1 agonists vs placebo

HbA1c (%) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 283 participants
Moderate

GLP‐1 agonists vs placebo

FBG (mmol/L) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 231 participants
Very low

GLP‐1 agonists vs placebo

Death (all causes) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 301 participants
Very low

GLP‐1 agonists vs placebo

All cardiovascular death · people with diabetes and CKD

The review found no eligible studies for this question.

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GLP‐1 agonists vs placebo

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 303 participants
Low

GLP‐1 agonists vs placebo

eGFR · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 279 participants
Low

GLP‐1 agonists vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 303 participants
Low

GLP‐1 agonists vs placebo

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 303 participants
Low

GLP‐1 agonists vs placebo

PD motor impairment · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

GLP‐1 agonists vs placebo

Health‐related quality of life · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

GLP‐1 agonists vs placebo

Serious adverse events · adults with Parkinson's disease

The review found no eligible studies for this question.

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GLP‐1 agonists vs placebo

Adverse events ‐ weight loss · adults with Parkinson's disease

GLP‐1 receptor agonists showed no clear difference in adverse events ‐ weight loss compared with placebo (low certainty).

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
RR 1.25 [0.89, 1.76]
1 study · 60 participants
Low

GLP‐1 agonists vs no treatment

PD motor impairment · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

GLP‐1 agonists vs no treatment

Health‐related quality of life · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

GLP‐1 agonists vs no treatment

Serious adverse events. · adults with Parkinson's disease

It is very uncertain whether GLP‐1 receptor agonists changes serious adverse events. compared with no treatment (very low certainty).

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
RR 1.6 [0.4, 6.32]
1 study · 44 participants
Very low

GLP‐1 agonists vs no treatment

Adverse events ‐ weight loss · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

GLP‐1RA vs placebo

Cardiovascular mortality · CVD (ASCVD, HF, or both)

GLP‐1RA leads to lower cardiovascular mortality compared with placebo (high certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes only
OR 0.87 [0.79, 0.95]
6 studies · 46093 participants
High

GLP‐1RA vs placebo

Fatal or nonfatal myocardial infarction · CVD (ASCVD, HF, or both)

GLP‐1RA showed no clear difference in myocardial infarction (fatal or non‐fatal) compared with placebo (moderate certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes only
OR 0.89 [0.78, 1.01]
5 studies · 42910 participants
Moderate

GLP‐1RA vs placebo

Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)

GLP‐1RA leads to lower stroke (fatal or non‐fatal) compared with placebo (high certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes only
OR 0.87 [0.77, 0.98]
5 studies · 42910 participants
High

GLP‐1RA vs placebo

All‐cause mortality · CVD (ASCVD, HF, or both)

GLP‐1RA leads to lower all‐cause mortality compared with placebo (high certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes only
OR 0.88 [0.82, 0.95]
7 studies · 46393 participants
High